Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy
Jerome Barakos(Sutter Health), Everard G.B. Vijverberg(Amsterdam Neuroscience), Joyce Suhy(BioClinica (United States)), C Grassi(Biogen (United States)), Carmen Castrillo‐Viguera(Biogen (United States)), I. Alex Rubino(Biogen (United States)), Spyros Chalkias(Moderna Therapeutics (United States)), Paul A. Burkett(Moderna Therapeutics (United States)), Derk D. Purcell(BioClinica (United States))
Cited by 154
Related Papers
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease
|The Journal of Prevention of Alzheimer s Disease|2022|1.3k
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
|New England Journal of Medicine|2022|649